Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

Ayoade Joy Ademuyewo says that anesthesiology is “the coolest thing in the world.” That’s why she became a certified registered nurse anesthetist.

And that career, which she says is “the perfect blend of science and art,” led to the creation of her startup, Lokum.

Lokum App is a matchmaking engine that aims to connect Ademuyewo’s peers with jobs. She explains that before her innovation, staffing for nurse anesthetists traditionally owed to job boards 30 years older than she was or to recruitment agencies that left them at a disadvantage.

“I didn't want to use that job board because it was sort of difficult to use and I didn't want to use it and a lot of other people felt the same way,” she recalls.

When a desperate friend asked for her help navigating the terrain of finding CRNA work as an independent contractor, Ademuyewo says the wheels began turning in her mind.

“I just thought, 'Why can't I open up my phone and see all of the available jobs to me, based on my preferences and my skills? And I can easily select from them to go to my next job.' And that's sort of where the questions started. And I just kept asking those questions. And I think about two or three years into asking the questions I was like, 'Oh my gosh, I think I'm starting a company,'” Ademuyewo says.

In the hours that she wasn’t in surgery, the CRNA began doing market research.

“As I was studying the market, and mapping it out, these really complex mind maps started to happen. And it was almost a natural conclusion that the more you understand the problem, the more the solution starts to appear to you,” she explains.

And she saw that the obvious solution was also potentially a big opportunity for her to create something entirely new — neither a job board nor an agency, but something entirely new. Ademuyewo calls Lokum a “matchmaking engine.” It takes the preferences, specialties and skills of CRNAs like her and matches them to jobs that make sense for them. To date, the pilot has connected users with around 200 hospitals and clinics in 20 states.

Fortunately, because there are so few CRNAs in practice, they are a unified bunch.

“It’s a really well-networked profession,” says Ademuyewo. “ I'm lucky to be in a profession where what we do is really special and really specialized.”

Because she was already part of the tight knit community, the founder had no trouble finding pilot customers. She worked with Houston-based Octaria Software to engineer the technical side of the app, as well as another local cybersecurity firm to work on infrastructure.

Lots of big news has come for Ademuyewo in the first half of 2024. She participated in this year’s cohort of the Google for Startups Accelerator Program-North America, which she says helped to gain traction in her fundraising amid a bear market.

The result? Early this month, Lokum announced a raise of $700,000 in pre-seed funding, which will be allocated to improving and enhancing the existing technology. Those funds came from Houston investors including Aileen Allen, of the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. More came from the non-local JP Morgan and Techstars.

Today, Ademuyewo is devoted full-time to Lokum, though she still practices her favorite combination of science and art on weekends in order to maintain her licensure.

“I will always be clinical, that will never change,” she says. “Part of that is just staying close to the problem and the people who are experiencing it, I think that is exactly the right thing for me to be doing.”

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

Houston innovator raises pre-seed funding for health care staffing platform

just closed

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission.

"I'm incredibly proud to have earned the trust of my colleagues, investors, team, and mentors in solving this complex problem."

Ademuyewo raised the round with support from local investors, including Aileen Allen, an adviser and investor associated with the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. Techstars and JP Morgan also contributed to the round.

"Lokum has found a way to disrupt an organically inefficient and expensive market with an elegant solution that doesn't just save hospitals time and money, but also increases the pool of specialty providers in a market that is consistently strapped for such expertise," Jerry Varnado, venture partner at South Loop Ventures, adds. "This is what disruption in healthcare looks like — scalable commercial solutions that contribute towards better patient care, and we're happy to be part of Lokum's journey."

Ademuyewo has the idea to start Lokum after her experience as an independent contract nurse anesthetist amid the height of the pandemic as she witnessed third-party recruitment agencies take advantage of medical professionals like herself.

Now, the platform's early pilot, which focuses on clinicians in anesthesiology, has served clients across nearly 200 hospitals and surgery centers in 20 states. Ademuyewo also participated in 2024’s cohort for the Google for Startups Accelerator Program-North America, where she spent 10 weeks developing and building her company and platform.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.